Evidence map›Paper›PMID 26449716›Full record

ReviewCurrent hematologic malignancy reports2015

The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

A A Gru, B H Haverkos, A G Freud, J Hastings, N B Nowacki, C Barrionuevo, C E Vigil, R Rochford, Y Natkunam, R A Baiocchi and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Epstein-Barr Virus Encoded lncRNAs Control the Viral Lytic Switch.bioRxiv : the preprint server for biology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Exploration and analysis of differentially expressed genes in Epstein-Barr virus negative and positive plasmablastic lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

A A GruDepartment of Pathology, University of Virginia, Charlottesville, VA, USA.
B H HaverkosDivision of Hematology, University of Colorado, Denver, CO, USA.
A G FreudDepartment of Pathology, Ohio State University, Columbus, OH, USA.
J HastingsDivision of Dermatology, Ohio State University, Columbus, OH, USA.
N B NowackiDepartment of Pathology, Ohio State University, Columbus, OH, USA.
C BarrionuevoInstituto Nacional de Enfermedades Neoplásicas (INEN), Department of Pathology, Lima, Peru.
C E VigilDepartment of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
R RochfordDepartment of Immunology and Microbiology, University of Colorado, Denver, CO, USA.
Y NatkunamDepartment of Pathology, Stanford University, Stanford, CA, USA.
R A BaiocchiDivision of Hematology, and Comprehensive Cancer Center, The Ohio State University, B320 West 10th Avenue, Columbus, OH, 43210, USA.
P PorcuDivision of Hematology, and Comprehensive Cancer Center, The Ohio State University, B320 West 10th Avenue, Columbus, OH, 43210, USA. pierluigi.porcu@osumc.edu.
The Ohio State University · USStanford University · USUniversity of Colorado Denver · USInstituto Nacional de Enfermedades Neoplásicas · PEUniversity of Iowa Hospitals and Clinics · USUniversity of Virginia · US

Funding

NCI NIH HHS L30 CA189070
6 · The paper itself

Abstract

While Epstein-Barr virus (EBV) was initially discovered and characterized as an oncogenic virus in B cell neoplasms, it also plays a complex and multifaceted role in T/NK cell lymphomas. In B cell lymphomas, EBV-encoded proteins have been shown to directly promote immortalization and proliferation through stimulation of the NF-κB pathway and increased expression of anti-apoptotic genes. In the context of mature T/NK lymphomas (MTNKL), with the possible exception on extranodal NK/T cell lymphoma (ENKTL), the virus likely plays a more diverse and nuanced role. EBV has been shown to shape the tumor microenvironment by promoting Th2-skewed T cell responses and by increasing the expression of the immune checkpoint ligand PD-L1. The type of cell infected, the amount of plasma EBV DNA, and the degree of viral lytic replication have all been proposed to have prognostic value in T/NK cell lymphomas. Latency patterns of EBV infection have been defined using EBV-infected B cell models and have not been definitively established in T/NK cell lymphomas. Identifying the expression profile of EBV lytic proteins could allow for individualized therapy with the use of antiviral medications. More work needs to be done to determine whether EBV-associated MTNKL have distinct biological and clinical features, which can be leveraged for risk stratification, disease monitoring, and therapeutic purposes.

Indexed as

Epstein-Barr Virus InfectionsHumansKiller Cells, NaturalLymphoma, T-CellPrognosisEBVLatentLyticPrognosisT/NK-cell lymphoma

Identifiers

PMID26449716
PMCPMC4679542
OpenAlexW1849032606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.